Therapy Areas: Vaccines
OliX Pharmaceuticals Subsidiary mCureX Forges mRNA Technology Collaboration with ToolGen for Rare Eye Disease
16 June 2022 - - South Korea-based RNAi therapeutics developer OliX Pharmaceuticals, Inc's mCureX Therapeutics, Inc. subsidiary has recently signed a contract for joint research with ToolGen, Inc. to advance the development of gene therapy for rare eye diseases, leveraging mCureX's mRNA technology, the company said.

mCureX, specializing in mRNA vaccines and therapeutics, and ToolGen, having expertise in therapeutic gene-editing technologies, have been in active discussions since their signing of memorandums of understanding in August 2021.

The two companies plan to conduct gene corrections in ocular tissues using mCureX's mRNA technology and ToolGen's CRISPR/Cas9 gene-editing technology for the treatment of rare hereditary eye diseases.

OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology.

The company's core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference, which is considered the most efficient gene silencing technology.

Utilizing this proprietary asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target diseases locally, such as hypertrophic scarring, dry and wet age-related macular degeneration, subretinal fibrosis, and neuropathic pain.

OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

ToolGen is a biotech company with the CRISPR/Cas9 core technology in gene-editing. ToolGen's mission is to provide customers with innovative human gene/cell therapies and gene-edited animals or plants.

ToolGen's research and business are based on ToolGen's CRISPR/Cas9-essential patents. ToolGen is the first patent filer successfully demonstrating a CRISPR/Cas9 application in eukaryotic cells in the world.

ToolGen's CRISPR patents have been registered in ten countries, including the United States, Europe, China, Australia, and Japan.